Skip to main content

enfuvirtide (Fuzeon®)

 

Following a full submission

AWMSG advice

Status: Recommended

The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of enfuvirtide within NHS Wales for the treatment of patients with HIV-1. It has been agreed the following restrictions should apply to its use:

  1. Enfuvirtide should only be available to physicians in secondary care specialising in the management of patients with HIV.
  2. Enfuvirtide must be used in accordance with criteria defined in the product's SPC and the UK British HIV Association (BHIVA) guidelines.

AWMSG would also like to draw the attention of prescribers to the following statement: "AWMSG has concerns that reference in the Patient Product Information Sheet for enfuvirtide of returning vials to the pharmacy may be misinterpreted by patients and could result in them attempting to return a wider range of clinical waste to the pharmacy. Pharmacists, doctors and nurses may find it necessary to draw the attention of patients to the correct way to dispose of their clinical waste."

 Final Recommendation: enfuvirtide (Fuzeon) 124 (PDF, 59Kb)

Medicine details

Medicine name enfuvirtide (Fuzeon®)
Formulation 90 mg/ml powder and solvent for solution for injection
Reference number 124
Indication

In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens

Company Roche Products Ltd
BNF chapter Infections
Assessment type Full
Status Recommended
AWMSG meeting date 02/12/2003
Ratification by Welsh Government 01/03/2004
Date of issue 28/05/2004
Follow AWTTC: